The drugmaker Altimmune says its new weekly injectable, pemvidutide, saw patients lose about 75% fat and only 25% muscle in results of a Phase II clinical trial the company announced on Wednesday
J Biol Chem (2013) 288(7):451321.10.1074/jbc.M112.402677 23 WangJHInoueTHigashiyamaMGuthPHEngelEKaunitzJDet alUmami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats
Results vary by individual, and effectiveness is usually evaluated after 6 months of treatment
Shifts in hormones and metabolism may also contribute to breakouts, dryness, or other complexion changes
In addition, with different periods of autophagy flux, diabetic retinopathy may progress under these scenarios [43]
As such, both the generation and function of active GLP-1 have become important aspects of type 2 diabetes (T2D) research 2